title: Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
authors.affiliation: University Hospital, Nantes, France philippe.moreau@chu-nantes.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine.
authors.forename: Halyna
authors.initials: H
authors.lastname: Pylypenko
authors.affiliation: Medical University of Silesia, Katowice, Poland.
authors.forename: Sebastian
authors.initials: S
authors.lastname: Grosicki
authors.affiliation: Kiev BMT Center, Kiev, Ukraine.
authors.forename: Ievgenii
authors.initials: I
authors.lastname: Karamanesht
authors.affiliation: Hopital Huriez, CHRU, Lille, France.
authors.forename: Xavier
authors.initials: X
authors.lastname: Leleu
authors.affiliation: Khmelnitskiy Regional Hospital, Khmelnitskiy, Ukraine.
authors.forename: Grigoriy
authors.initials: G
authors.lastname: Rekhtman
authors.affiliation: SI Institute of Blood Pathology and Transfusion Medicine UAMS, Lviv, Ukraine.
authors.forename: Zvenyslava
authors.initials: Z
authors.lastname: Masliak
authors.affiliation: Medical University of Lodz, Lodz, Poland.
authors.forename: Pawel
authors.initials: P
authors.lastname: Robak
authors.affiliation: Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.
authors.forename: Dixie-Lee
authors.initials: DL
authors.lastname: Esseltine
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ, USA.
authors.forename: Huaibao
authors.initials: H
authors.lastname: Feng
authors.affiliation: Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: William
authors.initials: W
authors.lastname: Deraedt
authors.affiliation: Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium.
authors.forename: Helgi
authors.initials: H
authors.lastname: van de Velde
authors.affiliation: Immuno-hématologie Department, Hôpital Saint-Louis, Paris, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Arnulf
mesh_terms: D000279:Administration, Cutaneous; D061605:Administration, Intravenous; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001897:Boronic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D000069286:Bortezomib; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009364:Neoplasm Recurrence, Local; D011719:Pyrazines / Q000008:administration & dosage* / Q000009:adverse effects; D051437:Renal Insufficiency / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib
keywords: MM patients; intravenous bortezomib; relapsed multiple myeloma; renally impaired